Internal Server Error

ALX Oncology - About the company

ALX Oncology is a public company based in Burlingame (United States), founded in 2015 by Corey Goodman and Kipp Weiskopf D. It operates as a Developer of immuno-oncology therapies for cancer treatment. ALX Oncology has raised $123M in funding from Vivo Capital. The company has 3408 active competitors, including 1139 funded and 785 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of immuno-oncology therapies for cancer treatment. The lead product candidate ALX148 is a checkpoint inhibitor that comprises an affinity CD47 binding domain of SIRPα linked to an inactive Fc region of a human immunoglobulin. It binds CD47 and inhibits the CD47-SIRPα signaling pathway.
Social
X
Email ID
*****@alxoncology.com
Registered Address
South San Francisco,California
Key Metrics
Founded Year
2015
Location
Burlingame, United States
Stage
Public
Total Funding
$123M in 2 rounds
Latest Funding Round
Ranked
Annual Revenue
$1M - $10M as on Dec 31, 2020
Employee Count
63 as on Oct 31, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public

ALX Oncology's IPO details

ALX Oncology got listed on Jul 17, 2020.
Click here to take a look at ALX Oncology's IPO in detail
Sign up to download ALX Oncology's company profile

ALX Oncology's funding and investors

ALX Oncology has raised a total funding of $123M over 2 rounds. Its first funding round was on May 21, 2015. Its latest funding round was a Series C round on Feb 12, 2020 for $*****. 9 investors participated in its latest round. ALX Oncology has 12 institutional investors.

Here is the list of recent funding rounds of ALX Oncology:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Feb 12, 2020
3570436
Series C
2204782
4420494
1841852
4321202
May 21, 2015
5237205
Series A
4491333
1674846
2954682
1873493
lockAccess funding benchmarks and valuations. Sign up today!

ALX Oncology's founders and board of directors

Founder? Claim Profile
The founders of ALX Oncology are Corey Goodman and Kipp Weiskopf D.
Here are the details of ALX Oncology's key team members:

ALX Oncology's employee count trend

ALX Oncology has 63 employees as of Oct 26. Here is ALX Oncology's employee count trend over the years:
Employee count trend for ALX Oncology
lockUncover ALX Oncology's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

ALX Oncology's Competitors and alternates

Top competitors of ALX Oncology include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of ALX Oncology, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Jazz Pharmaceuticals
Jazz Pharmaceuticals
2003, Dublin (Ireland), Public
Developer of novel biopharmaceutical medicines for unmet medical needs
$265M
81/100
2nd
Logo for BeiGene
BeiGene
2010, Cambridge (United States), Public
Developer of targeted and immune-oncology drugs against cancer
$172M
81/100
3rd
Logo for Sana Biotechnology
Sana Biotechnology
2018, Seattle (United States), Public
Developer of engineered cell therapies for treating various human diseases
$821M
74/100
4th
Logo for Ideaya Biosciences
Ideaya Biosciences
2015, San Francisco (United States), Public
Developer of oncology-focused precision medicine using molecular diagnostics
$157M
73/100
5th
Logo for Senti Bio
Senti Bio
2016, San Francisco (United States), Public
Developer of cell and gene therapies for patients living with incurable diseases
$158M
72/100
6th
Developer of antibody-based therapeutics for cancer therapy
$175M
72/100
7th
Logo for Syndax
Syndax
2005, Waltham (United States), Public
Developer of targeted therapies for the treatment of cancer
$198M
72/100
8th
Logo for Moderna
Moderna
2010, Cambridge (United States), Public
Developer of mRNA-based therapeutics for a wide range of diseases
$2.78B
72/100
9th
Logo for Immuneel
Immuneel
2018, Bengaluru (India), Series B
Developer of T-cell therapies for the treatment of cancer
$49.8M
72/100
10th
Logo for C4 Therapeutics
C4 Therapeutics
2016, Cambridge (United States), Public
Developer of small molecule drugs for treating cancer
$223M
71/100
208th
Logo for ALX Oncology
ALX Oncology
2015, Burlingame (United States), Public
Developer of immuno-oncology therapies for cancer treatment
$123M
56/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on ALX Oncology's competitors? Click here to see the top ones

ALX Oncology's Investments and acquisitions

ALX Oncology has acquired ScalmiBio. ALX Oncology has not made any investments as of now.

Reports related to ALX Oncology

Here is the latest report on ALX Oncology's sector:

News related to ALX Oncology

lockFilter this list
Media has covered ALX Oncology for a total of 14 events in the last 1 year, 10 of them have been about company updates and 1 about people movement.
•
ALX Oncology Announces Phase Ib/II Trial Results for Breast Cancerclinicaltrialsarena.com•Feb 02, 2026•ALX Oncology
•
ALX Oncology Announces Pricing of Underwritten OfferingGlobeNewswire•Jan 30, 2026•ALX Oncology
•
ALX Oncology Advances Clinical Trials of Evorpacept and ALX2004GlobeNewswire•Jan 08, 2026•ALX Oncology
•
ALX Oncology to Present at Upcoming Investor ConferencesBenzinga•Nov 18, 2025•ALX Oncology
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about ALX Oncology

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford